Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Human & Experimental Toxicology|February 21, 2013
Probucol and the cholesterol synthesis inhibitors simvastatin and triparanol regulate I ks channel function differentlyTaro Hihara, Tomohiko Taniguchi, Masataka Ueda, et al.
Toxicology in Vitro : an International Journal Published in Association with BIBRA|December 27, 2011
A novel method of selecting human embryonic stem cell-derived cardiomyocyte clusters for assessment of potential to influence QT intervalKazuto Yamazaki, Taro Hihara, Tomohiko Taniguchi, et al.
Journal of Pharmacological Sciences|September 9, 2008
Antidiabetic and hypolipidemic effects of a novel dual peroxisome proliferator-activated receptor (PPAR) alpha/gamma agonist, E3030, in db/db mice and beagle dogsShunji Kasai, Takashi Inoue, Hideki Yoshitomi, et al.
European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Fur Pharmazeutische Verfahrenstechnik E.V|January 5, 2023
Multivalent mannose-conjugated siRNA causes robust gene silencing in pancreatic macrophages in vivoKazuto Yamazaki, Kenji Kubara, Yuta Suzuki, et al.
Toxicological Sciences : an Official Journal of the Society of Toxicology|October 3, 2013
E2012-induced cataract and its predictive biomarkersKyoko Nakano-Ito, Yasuhiro Fujikawa, Taro Hihara, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|July 24, 2020
Tumor-related mutations in cell-free DNA in pre-operative plasma as a prognostic indicator of recurrence in endometrial cancerDaisuke Shintani, Taro Hihara, Aiko Ogasawara, et al.
International Journal of Pharmaceutics|August 23, 2020
PEG shedding-rate-dependent blood clearance of PEGylated lipid nanoparticles in mice: Faster PEG shedding attenuates anti-PEG IgM productionTakuya Suzuki, Yuta Suzuki, Taro Hihara, et al.
Cancer Research and Treatment|July 1, 2020
Evaluation of Circulating Tumor DNA in Patients with Ovarian Cancer Harboring Somatic PIK3CA or KRAS MutationsAiko Ogasawara, Taro Hihara, Daisuke Shintani, et al.
CPT: Pharmacometrics & Systems Pharmacology|March 26, 2024
Population pharmacokinetic-pharmacodynamic modeling of serum biomarkers as predictors of tumor dynamics following lenvatinib treatment in patients with radioiodine-refractory differentiated thyroid cancer (RR-DTC)Oneeb Majid, Seiichi Hayato, Sree Harsha Sreerama Reddy, et al.
European Journal of Cancer (Oxford, England : 1990)|February 27, 2017
Exploratory analysis of biomarkers associated with clinical outcomes from the study of lenvatinib in differentiated cancer of the thyroidMakoto Tahara, Martin Schlumberger, Rossella Elisei, et al.
Pageof 2